home · filing · 0001193125-21-228185
8-K filed July 29, 2021, 7:59 PM ET
ticker KURA
CIK 0001422143
leadership
confidence high
sentiment neutral
materiality 0.25
Kura Oncology appoints Helen Collins, M.D. as Class II director
Kura Oncology, Inc.
Appointed effective July 28, 2021; term expires at 2022 annual meeting.
Previously EVP and CMO at Five Prime Therapeutics, led bemarituzumab development until Amgen acquisition in April 2021.
Received options for 46,000 shares (3-year vest) and 19,166 shares (1-year vest); annual cash retainer $40,000.
Annual automatic option grants of 23,000 shares on each annual meeting date, vesting over one year.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Appointed
Helen Collins, M.D.
Class II director
KURA ·
Kura Oncology, Inc.
Effective 2021-07-28
Filed July 29, 2021, 7:59 PM ET
appointed Helen Collins, M.D. as a Class II director of the Company
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
Helen Collins, M.D. was appointed as Class II director at Kura Oncology, Inc..
Action appointed
Role Class II director
Exact text from the filing
appointed Helen Collins, M.D. as a Class II director of the Company
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-228185
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.